DEAN R. DRAGOLI,HIROKO TANAKA,JAY P. POWERS,PENGLIE ZHANG,PINGCHEN FAN,SREENIVAS PUNNA,XI CHEN,YANDONG LI
申请号：
BR112015004254
公开号：
BR112015004254A2
申请日:
2013.08.27
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
antagonists of chemokine receptors Abstract of the disclosure compounds are provided that act as potent antagonists of the ccr1 receptor, and have in vivo anti-inflammatory activity. the compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr1-mediated diseases, and the controls in assays for the identification of competitive ccr1 antagonists. translation of the abstract patent summary for "chemokine receptor antagonists". Compounds are provided which act as potent ccr1 receptor antagonists, and have anti-inflammatory activity in vivo. The compounds are generally derived from aryl piperazine and are pharmaceutical compositions, methods for treating ccr1-mediated diseases, and as controls in assays for the identification of competitive ccr1 antagonists.antagonists of chemokine receptors abstract of the disclosure compounds are provided that act as potent antagonists of the ccr1 receptor, and have in vivo anti-inflammatory activity. the compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr1-mediated diseases, and as controls in assays for the identification of competitive ccr1 antagonists. tradução do resumo resumo patente de invenção para "antagonistas dos receptores de quimiocina". compostos são fornecidos os quais agem como antagonistas potentes do receptor ccr1, e têm atividade anti-inflamatória in vivo. os compostos são geralmente derivados de aril piperazina e são composições farmacêuticas, métodos para o tratamento de doenças mediadas por ccr1, e como controles em ensaios para a identificação de antagonistas de ccr1 competitivos.
